ClinicalTrials.gg
CompletedNCT06843993Updated Feb 25, 2025

Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)

A Phase 1 interventional study of MK-2060 and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to male participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry.
  • Registered 1 year 11 months after the study started (first participant enrolled Mar 2023, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
Male
01

Study summary

The goal of the study is to learn about the safety of MK-2060 and if people tolerate it. Researchers also want to learn what happens to MK-2060 in a person's body over time.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a (BMI) ≥18 and ≤28 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer ()
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Panel A: MK-2060 Dose 1

    MK-2060 dose 1 was administered as a single intravenous (IV) infusion dose on Day 1.

    Biological: MK-2060

  • Experimental
    Panel B: MK-2060 Dose 2

    MK-2060 dose 2 was administered as a single IV infusion dose on Day 1. There was at least a 21-day period between dosing in Panel A and B.

    Biological: MK-2060

  • Experimental
    Panel C: MK-2060 Dose 3

    MK-2060 dose 3 was administered as a single IV infusion dose on Day 1. There was at least a 21-day period between dosing in Panel B and C.

    Biological: MK-2060

  • Placebo comparator
    Placebo

    Placebo was administered as a single IV infusion over MK-2060-matched time period on Day 1.

    Biological: Placebo

Interventions

  • BiologicalMK-2060

    Single doses of MK-2060 administered via IV infusion on Day 1 according to randomization.

  • BiologicalPlacebo

    Single doses of placebo administered via IV infusion on Day 1 according to randomization.

06

What researchers measure

Primary outcomes

  1. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 164 days

  2. Number of participants who discontinue study due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 164 days

  3. Number of participants who experience one or more AEs related to bleeding

    A bleeding related AE includes any sign or symptom of bleeding even if not requiring intervention by a medical/ healthcare professional, to clinically-relevant non major bleeding or major bleeding.

    Time frame: Up to 164 days

Secondary outcomes

  1. Plasma concentration at end of infusion (Ceoi) of MK-2060

    Ceoi is defined as the amount of MK-2060 in plasma following IV infusion administration of MK-2060. Blood samples were collected at pre-specified time points to assess Ceoi.

    Time frame: Predose Day 1 and end of infusion

  2. Plasma concentration at 168 hours (C168hr) of MK-2060

    C168 is defined as the maximum concentration of MK-2060 reached at 168 hours postdose. Blood samples were collected at pre-specified time points to assess C168hr.

    Time frame: At designated timepoints (up to 168 hours)

  3. Area under the concentration versus time curve from 0 to infinity (AUC0-inf) of MK-2060

    AUC0-inf is defined as the area under the concentration-time curve of MK-2060 from time zero to infinity. Blood samples were collected at pre-specified time points to assess AUC0-inf.

    Time frame: At designated timepoints (up to 150 days)

  4. AUC from 0 to 168 hours (AUC0-168) of MK-2060

    AUC0-168 is defined as the area under the concentration-time curve of MK-2060 from time zero to 168 hours. Blood samples were collected at pre-specified time points to assess AUC0-168.

    Time frame: At designated timepoints (up to 168 hours)

  5. Time to maximum observed plasma drug concentration (Tmax) of MK-2060

    Tmax is defined as time to the maximum concentration of MK-2060 reached. Blood samples were collected at pre-specified time points to assess Tmax.

    Time frame: At designated timepoints (up to 150 days)

  6. Terminal half-life of MK-2060

    t½ is defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-2060. Blood samples were collected at pre-specified time points to assess terminal half-life.

    Time frame: At designated timepoints (up to 150 days)

  7. Clearance (CL) of MK-2060

    CL is the volume of plasma from which MK-2060 is completely removed per unit time. Blood samples were collected at pre-specified time points to assess CL.

    Time frame: At designated timepoints (up to 150 days)

  8. Volume of distribution (Vz) of MK-2060

    Vz is defined as the distributed volume of MK-2060 in plasma. Blood samples were collected at pre-specified time points to assess Vz.

    Time frame: At designated timepoints (up to 150 days)

  9. Change from baseline in activated partial thromboplastin time (aPTT)

    Blood samples were collected at pre-specified time points to assess change from baseline in aPTT.

    Time frame: Baseline (pre-dose) Day 1 and at designated timepoints (up to 150 days)

  10. Anti-drug antibodies (ADA) positive incidence

    Blood samples were collected at pre-specified time points to assess the incidence of anti-MK-2060 antibodies.

    Time frame: At designated timepoints (up to 150 days)

  11. Factor XI (FXI) activity level

    Blood samples were collected at pre-specified time points to assess FXI activity level.

    Time frame: At designated timepoints (up to 150 days)

  12. Prothrombin time (PT)

    Blood samples were collected at pre-specified time points to assess PT.

    Time frame: At designated timepoints (up to 150 days)

07

Study locations

1 site
  • Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 001)
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Oct 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Mar 1, 2023
Primary completionActual
Oct 27, 2023
CompletionActual
Oct 27, 2023
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06843993
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Mar 1, 2023
Primary completion
Oct 27, 2023
Completion
Oct 27, 2023
Last update
Feb 25, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-2060

Start the discussion